Member area login

You don't have or don't remember the password!
Click Here

Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Andrea di Bello
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da E. La Civita

Current trends and future directions of liquid biopsy in renal cell carcinoma

E. La Civita \| A. Liotti \| M. Cennamo \| L. Conte \| E. Grassia \| D. Terracciano \|
<p>Metastatic clear cell renal cell carcinoma is a high vascularized and aggressive tumor characterized by a high intra-tumoral and inter-tumoral heterogeneity. For this reason, despite the wide range of therapy available, these patients often show resistance to chemotherapy. In this scenario, it could be of great benefit the discovery of biomarkers to identify the most suitable treatment for first and second line therapy and the early determination of outcome. Once identified, circulating biomarkers could be introduced in clinical practice and integrated with patient’s clinical features for building a decision algorithm usable by clinicians. The liquid biopsy, defined as the determination in fluids like blood of tumor-released product such as DNA, RNA and protein, exhibits several advantages over tissue biomarkers including a real time correlation with tumor features, lower cost and lower risk for the patient. Our understanding of the liquid biopsy has raised rapidly in the last few years accordingly with the development of new molecular biology techniques. Efforts are under way for the identification of robust and reproducible liquid biopsy assays that could improve soon overall survival (OS) and quality of life of metastatic renal cell carcinoma.</p>
Biochimica Clinica ; 17(1) Rassegne - Reviews